Postdoctoral Training Fellow - Quantitative Cancer Biology

13/06/2021, 23:55

Molecular Pathology
Tumour Func Heterogeneity
Full time
Fixed Term
3 years
£38, 607 per annum (£32,844 as a starting salary for pre-viva applicants)
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top five cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

The Tumour Functional Heterogeneity (TFH) team, led by Dr Marco Bezzi, combines preclinical modelling, functional genomics approaches and multi-parameter single cell analysis to investigate tumour heterogeneity. Two major research areas of the lab are i) identification of cancer trajectories of convergent evolution in response to therapy and ii) mechanisms of co-operation between cancer clones within their microenvironmental context. Ultimately, the TFH lab aims to design innovative therapeutic approaches that exploit cancer vulnerabilities and anticipate drug resistance. The TFH lab is part of Centre for Evolution and Cancer and of the Division of Molecular Pathology. It is located at the newly built, multidisciplinary Centre for Cancer Drug Discovery in Sutton, London. 

 We are looking for an enthusiastic postdoctoral research fellow to deliver a CRUK funded research program that will shed light on how intra-tumoural phenotypic diversity affects clonal dynamics and their interaction with the tumour microenvironment. The successful candidate will collaborate with other members of the lab to generate high-dimensional datasets (CyTOF, CODEX and scRNA-seq) using organoids and in vivo models of prostate cancer. The post-holder will be leading on the bioinformatics analysis under the supervision of the team leader and the co-supervision of Prof Andrea Sottoriva, leader of the Evolutionary Genomics and Modelling team.

 The ideal candidate holds a PhD/DPhil (or near completion) in bioinformatics or computational biology with a strong background in cancer biology and an undergraduate degree in molecular biology or similar subject. Significant wet-lab experience in sample preparation for high-parameter cell suspension profiling, multiplexed spatial tissue imaging and single-cell RNA sequencing would be an advantage. Demonstrable R programming skills and experience of analysis of CyTOF data are essentials. Informal enquires are welcome and can be made to Dr Marco Bezzi (

To apply, please submit an application on the ICR Careers site, attaching your CV with the supporting statement (addressing with specific examples where you meet the person specification, a brief description of your relevant experience and incl. the names and addresses of at least two referees). 


We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

The ICR is the leading academic research centre in the UK. Effective industry collaboration and innovation in new medicines and technologies are at the heart of our approach to drive benefits for patients. The ICR is ranked:


  • first for the quality and impact of our research*
  • second worldwide for the number of our publications cited in patents**
  • fourth worldwide for the citation rate of scientific research published across all fields**
  • fourth worldwide for top-cited research publications**
  • in the top five higher education institutions worldwide for academic influence and commercial impact**


*2014 Research Excellence Framework

** U-Multirank, 2020

Funded by

Cancer Research UK
Additional Documentation for Candidates

This Program is closed to applications.